23:52 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting HNF1A could help treat pancreatic ductal adenocarcinoma (PDAC). In PDAC patient samples, high tumor expression of a HNF1A-induced gene signature was associated with...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Forkhead box A1 (FOXA1); FOXA2; FOXA3; GATA binding protein 4 (GATA4); HNF1 homeobox A (HNF1A); hepatocyte nuclear factor 4 α (HNF4A; TCF) FOXA3,

Hepatic disease INDICATION: Liver fibrosis Mouse studies suggest in vivo reprogramming of liver myofibroblasts into hepatocyte-like cells could help treat liver fibrosis. In a mouse model of the disease, in vivo transduction of myofibroblasts with...
07:00 , Mar 20, 2014 |  BC Innovations  |  Cover Story

A liver divided

Three separate teams have directly converted human fibroblasts to proliferative liver cells and thus eliminated a key drawback of using induced pluripotent stem cells to treat damaged livers-the inability of the resulting differentiated cells to...
08:00 , Feb 26, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Coronary artery disease (CAD) Muscle RAS oncogene homolog (MRAS); HNF1 homeobox A (HNF1A); solute carrier family 22 (extraneuronal...